AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33086312 — intervention group
Group type: EXPERIMENTAL
Intervention: Low aFXa levels (initial low aFXa)
Number of subjects: 985
Study 33086312 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily enoxaparin
Number of subjects: 985
Study 33086312 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily enoxaparin
Number of subjects: 985
Study 33086312 — intervention group
Group type: EXPERIMENTAL
Intervention: High aFXa levels
Number of subjects: 985
Study 33086913 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for data collection
Number of subjects: 2000
Study 33087092 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 213
Study 33087092 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 213
Study 33087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency
Number of subjects: 109
Study 33087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 109
Study 33087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation markers
Number of subjects: 109
Study 33087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperferritinemia
Number of subjects: 109
Study 33087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe lung pathologies
Number of subjects: 109
Study 33087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status
Number of subjects: 109
Study 33087142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation with a fractionated marine lipid concentration standardized to 17-HDHA and 18-HEPE for 4 weeks
Number of subjects: 44
Study 33087171 — intervention group
Group type: EXPERIMENTAL
Intervention: K-means clustering algorithm for cognitive phenotypes
Number of subjects: 156
Study 33087171 — intervention group
Group type: COMPARATOR
Intervention: Classical approach of cognitive impairment assessment
Number of subjects: 156
Study 33087171 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid treatment
Number of subjects: 156
Study 33087171 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables
Number of subjects: 156
Study 33087171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reserve
Number of subjects: 156
Study 33087150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 301
Study 33087333 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg (for bodyweight ≥50 kg) or 3 mg/kg (for bodyweight <50 kg) every 2 weeks plus oral apatinib 250 mg daily
Number of subjects: 190
Study 33087333 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 190
Study 33087340 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-enabled diabetic retinopathy screening using a deep learning algorithm
Number of subjects: 47269
Study 33087340 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-enabled diabetic retinopathy screening
Number of subjects: 47269
Study 33087345 — intervention group
Group type: EXPERIMENTAL
Intervention: nTreg infusion (0.5, 1.0, or 2.5-3.0×10^6 cells)
Number of subjects: 11
Study 33087345 — intervention group
Group type: COMPARATOR
Intervention: Reference group (standard dual or triple drug immunosuppression)
Number of subjects: 11
Study 33087380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, inflammatory, genetic, microbiome and metabolomic profiles in patients with IBS and IBD
Number of subjects: 8000
Study 33087380 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 8000
Study 33087380 — intervention group
Group type: EXPERIMENTAL
Intervention: Active disease
Number of subjects: 8000
Study 33087380 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological comorbidity
Number of subjects: 8000
Study 33087451 — intervention group
Group type: EXPERIMENTAL
Intervention: Students 4 Best Evidence (S4BE) platform as a digital Problem-Based Learning (DPBL) method
Number of subjects: 121
Study 33087548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT lung cancer screening (LDCT)
Number of subjects: 787
Study 33087548 — intervention group
Group type: COMPARATOR
Intervention: Community sample
Number of subjects: 787
Study 33087746 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (3 hours sleep opportunity at the end of night)
Number of subjects: 69
Study 33087746 — intervention group
Group type: COMPARATOR
Intervention: Full sleep condition
Number of subjects: 69
Study 33087746 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation
Number of subjects: 69
Study 33088015 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 498
Study 33088573 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT-sMF (photobiomodulation therapy combined with static magnetic field)
Number of subjects: 60
Study 33088573 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT-sMF
Number of subjects: 60
Study 33088581 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week cooking intervention delivered at a community kitchen setting
Number of subjects: 0
Study 33089005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release transdermal nicotine
Number of subjects: 0
Study 33089005 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 33089069 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 25
Study 33089304 — intervention group
Group type: EXPERIMENTAL
Intervention: CDR132L (monthly intravenous treatments over 3 or 5 months)
Number of subjects: 0
Study 33089304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 33089492 — intervention group
Group type: COMPARATOR
Intervention: Educational interventions
Number of subjects: 2832
Study 33089492 — intervention group
Group type: COMPARATOR
Intervention: Behavioural interventions (intensive reminders)
Number of subjects: 2832
Study 33089492 — intervention group
Group type: COMPARATOR
Intervention: Mixed interventions
Number of subjects: 2832
Study 33089492 — intervention group
Group type: COMPARATOR
Intervention: Various interventions (including educational and behavioural)
Number of subjects: 2832
Study 33089492 — intervention group
Group type: COMPARATOR
Intervention: Self-efficacy and quality of life interventions
Number of subjects: 2832
Study 33089502 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin inhibitors (RIs)
Number of subjects: 13627
Study 33089502 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 13627
Study 33089593 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of treatment for bipolar disorder
Number of subjects: 42
Study 33089593 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison group (n=41)
Number of subjects: 42
Study 33089824 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-IMS (multicapillary column coupled ion mobility spectrometry)
Number of subjects: 24
Study 33089824 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy staff and patients with negative PCR)
Number of subjects: 24
Study 33089874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat (TAK-924/MLN4924)
Number of subjects: 0
Study 33089892 — intervention group
Group type: EXPERIMENTAL
Intervention: Portosystemic shunts (TS, DSRS, TIPS)
Number of subjects: 1828
Study 33089892 — intervention group
Group type: EXPERIMENTAL
Intervention: TS
Number of subjects: 1828
Study 33089892 — intervention group
Group type: EXPERIMENTAL
Intervention: DSRS
Number of subjects: 1828
Study 33089892 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 1828
Study 33090077 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal fixation under sedation and local or epidural anesthesia
Number of subjects: 10
Study 33090333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (loading dose followed by weekly infusions of 250 mg/m2)
Number of subjects: 49
Study 33090333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 49
Study 33090368 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned fear task and magnetoencephalography to record pain-related fear responses in FM patients.
Number of subjects: 52
Study 33090368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin treatment in FM patients.
Number of subjects: 52
Study 33090970 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 3408
Study 33090970 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LAM)
Number of subjects: 3408
Study 33091124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood (CB)-derived adoptive cell therapy after salvage chemotherapy
Number of subjects: 31
Study 33091124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood (CB)-derived adoptive cell therapy
Number of subjects: 31
Study 33091791 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-friendly 3D bimanual protocol
Number of subjects: 20
Study 33091791 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children (TDC)
Number of subjects: 20
Study 33091843 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 67
Study 33091844 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone units distributed in HCS communities
Number of subjects: 0
Study 33091844 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-approved buprenorphine products
Number of subjects: 0
Study 33091844 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk opioid prescribing incidents
Number of subjects: 0
Study 33091844 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid overdose deaths
Number of subjects: 0
Study 33091842 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 67
Study 33091842 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdose education and naloxone distribution (OEND)
Number of subjects: 67
Study 33091842 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD)
Number of subjects: 67
Study 33091842 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer opioid analgesic prescribing
Number of subjects: 67
Study 33091891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectric neural interface
Number of subjects: 0
Study 33092403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment for 4 weeks
Number of subjects: 0
Study 33092403 — intervention group
Group type: COMPARATOR
Intervention: Acalabrutinib treatment for 4 weeks
Number of subjects: 0
Study 33092403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-specific Csk knockout in mice
Number of subjects: 0
Study 33092403 — intervention group
Group type: COMPARATOR
Intervention: Kinase inhibitors blocking Csk
Number of subjects: 0
Study 33092438 — intervention group
Group type: COMPARATOR
Intervention: hs-CRP level <1.0 mg/L
Number of subjects: 2018
Study 33092438 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP level
Number of subjects: 2018
Study 33092570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 398
Study 33092570 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 398
Study 33092588 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with non-ischemic LGE lesions
Number of subjects: 296
Study 33092646 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss treatment including Very Low Energy Diet (VLED)
Number of subjects: 41
Study 33092646 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Number of subjects: 41
Study 33092709 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 109
Study 33093033 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 testing via nasopharyngeal swab using reverse-transcriptase PCR
Number of subjects: 0
Study 33093033 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical data collection
Number of subjects: 0
Study 33093033 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate modelling
Number of subjects: 0
Study 33093337 — intervention group
Group type: EXPERIMENTAL
Intervention: Small molecule poly-ADP-ribosyl polymerase inhibitors
Number of subjects: 0
Study 33093337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel with immune checkpoint inhibitor antibodies
Number of subjects: 0
Study 33093337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 0
Study 33093408 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlifidase treatment
Number of subjects: 0
Study 33093900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal administration of bevacizumab (Lumiere)
Number of subjects: 0
Study 33094311 — intervention group
Group type: COMPARATOR
Intervention: PURE EP™ (PEP) system
Number of subjects: 10
Study 33094357 — intervention group
Group type: EXPERIMENTAL
Intervention: New patient-reported outcome measure (PROM) for financial toxicity (FT)
Number of subjects: 34
Study 33094474 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy (400 mg/day)
Number of subjects: 12
Study 33094474 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab (400 mg/day)
Number of subjects: 12
Study 33094498 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Number of subjects: 88
Study 33094498 — intervention group
Group type: COMPARATOR
Intervention: 99m Technetium (radioisotope)
Number of subjects: 88
Study 33094498 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method (Indocyanine green and 99m Technetium)
Number of subjects: 88
Study 33094498 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green and 99m Technetium
Number of subjects: 88
Study 33094734 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIO app-based cognitive-behavioral pain self-management intervention
Number of subjects: 50
Study 33094734 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIO intervention
Number of subjects: 50
Study 33094826 — intervention group
Group type: EXPERIMENTAL
Intervention: LiDCO CNAP (continuous non-invasive arterial pressure) device
Number of subjects: 104
Study 33095075 — intervention group
Group type: EXPERIMENTAL
Intervention: POCP visual impression of malignancy
Number of subjects: 66
Study 33095075 — intervention group
Group type: EXPERIMENTAL
Intervention: POCP-guided samples histological analysis
Number of subjects: 66
Study 33095075 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical success for lesion visualization
Number of subjects: 66
Study 33095075 — intervention group
Group type: EXPERIMENTAL
Intervention: Median VAS scores for insertions in bile and PD
Number of subjects: 66
Study 33095075 — intervention group
Group type: EXPERIMENTAL
Intervention: Median VAS score for access to the lesion
Number of subjects: 66
Study 33095075 — intervention group
Group type: EXPERIMENTAL
Intervention: Median VAS score for image quality
Number of subjects: 66
Study 33095075 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day complications
Number of subjects: 66
Study 33095117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine-based therapies
Number of subjects: 0
Study 33095117 — intervention group
Group type: EXPERIMENTAL
Intervention: C/CHOP-based therapies
Number of subjects: 0
Study 33095117 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil-based therapy
Number of subjects: 0
Study 33095117 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies (kinase inhibitors)
Number of subjects: 0
Study 33095117 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 0
Study 33095287 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib at 215 mg/m² in combination with cyclophosphamide and topotecan
Number of subjects: 44
Study 33095287 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib at 165 mg/m² and 280 mg/m²
Number of subjects: 44
Study 33095411 — intervention group
Group type: EXPERIMENTAL
Intervention: XC8 2 mg
Number of subjects: 120
Study 33095411 — intervention group
Group type: EXPERIMENTAL
Intervention: XC8 10 mg
Number of subjects: 120
Study 33095411 — intervention group
Group type: EXPERIMENTAL
Intervention: XC8 100 mg
Number of subjects: 120
Study 33095411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33095458 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 1563
Study 33095645 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette users
Number of subjects: 0
Study 33095645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 0
Study 33095645 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 0
Study 33095645 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 33095832 — intervention group
Group type: EXPERIMENTAL
Intervention: Social health
Number of subjects: 598
Study 33095832 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health
Number of subjects: 598
Study 33095832 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSS
Number of subjects: 598
Study 33095874 — intervention group
Group type: EXPERIMENTAL
Intervention: 64Cu-daratumumab PET/CT
Number of subjects: 12
Study 33095874 — intervention group
Group type: COMPARATOR
Intervention: Unlabeled daratumumab (0 mg, 10 mg, 45 mg, 95 mg)
Number of subjects: 12
Study 33096421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m²
Number of subjects: 20
Study 33096476 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-radiation treatment
Number of subjects: 89
Study 33096476 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein expression data by RPPA
Number of subjects: 89
Study 33097085 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-CHOP (tucidinostat plus R-CHOP)
Number of subjects: 49
Study 33097369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided radial artery cannulation
Number of subjects: 680
Study 33097612 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab (500 to 1000 mg) and Selicrelumab (2 to 16 mg) administered intravenously every 3 weeks
Number of subjects: 0
Study 33097687 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (3.4 mg/kg, every 3 weeks)
Number of subjects: 25
Study 33097974 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D convolutional neural network (CNN) for automatic segmentation of total metabolic tumour volume (TMTV)
Number of subjects: 733
Study 33098195 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant carboplatin (AUC 6) every 28 days for four cycles plus nab-paclitaxel (100 mg/m2)
Number of subjects: 69
Study 33098195 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant carboplatin and nab-paclitaxel
Number of subjects: 69
Study 33098526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 150
Study 33098548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 589
Study 33098548 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 589
Study 33098553 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with increased BMI
Number of subjects: 493
Study 33098553 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with increased BMI
Number of subjects: 493
Study 33099491 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotoxic hypofractionated concurrent chemoradiotherapy with docetaxel plus lobaplatin
Number of subjects: 30
Study 33099499 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet healthcare needs assessed via a standardised telephone assessment within 1 to 4 weeks after hospital discharge
Number of subjects: 200
Study 33099499 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life, cognitive impairment, depression, anxiety, and post-traumatic stress disorder
Number of subjects: 200
Study 33099636 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT TRICK intervention
Number of subjects: 62
Study 33099636 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators' experiences
Number of subjects: 62
Study 33099636 — intervention group
Group type: EXPERIMENTAL
Intervention: Future programme refinements
Number of subjects: 62
Study 33099678 — intervention group
Group type: EXPERIMENTAL
Intervention: arfolitixorin (at four dose levels)
Number of subjects: 33
Study 33099681 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1023
Study 33099681 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1023
Study 33099742 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone (0.5 mg for 24 weeks)
Number of subjects: 205
Study 33099742 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (15 mg for 24 weeks)
Number of subjects: 205
Study 33100036 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD support combined with standardized pharmacological therapy and cardiac function monitoring protocol
Number of subjects: 40
Study 33100059 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G4 Platinum
Number of subjects: 60
Study 33100426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 110
Study 33100426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CBT)
Number of subjects: 110
Study 33101027 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch containing Allium cepa and allantoin
Number of subjects: 93
Study 33101027 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch containing Allium cepa and allantoin (Group B)
Number of subjects: 93
Study 33101027 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 93
Study 33101068 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 204
Study 33101068 — intervention group
Group type: COMPARATOR
Intervention: Services-as-usual control condition
Number of subjects: 204
Study 33101079 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (De Simone Formulation)
Number of subjects: 85
Study 33101079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 33101178 — intervention group
Group type: EXPERIMENTAL
Intervention: REMOTE Ischemic Perconditioning
Number of subjects: 0